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Leber’s hereditary optic neuropathy (LHON) is a maternally transmitted disorder caused by point mutations in mitochondrial
DNA (mtDNA). Most cases are due to mutations in genes encoding subunits of the NADH-ubiquinone oxidoreductase that is
Complex I of the electron transport chain (ETC). These mutations are located at nucleotide positions 3460, 11778, or 14484
in the mitochondrial genome. The disease is characterized by apoplectic, bilateral, and severe visual loss. While the mutated
mtDNA impairs generation of ATP by all mitochondria, there is only a selective loss of retinal ganglion cells and degeneration
of optic nerve axons. Thus, blindness is typically permanent. Half of the men and 10% of females who harbor the pathogenic
mtDNA mutation actually develop the phenotype. This incomplete penetrance and gender bias is not fully understood. Additional
mitochondrial and/or nuclear genetic factors may modulate the phenotypic expression of LHON. In a population-based study, the
mtDNA background of haplogroup J was associated with an inverse relationship of low-ATP generation and increased production
of reactive oxygen species (ROS). Eﬀective therapy for LHON has been elusive. In this paper, we describe the ﬁndings of pertinent
published studies and discuss the controversies of potential strategies to ameliorate the disease.
1.Introduction
Leber’s hereditary optic neuropathy (LHON) refers to a
rare, neurodegenerative maternally inherited, mitochondrial
genetic disease. The clinical features of LHON were ﬁrst
described by the German ophthalmologist Theodor Leber,
in 1871 [1]. LHON is characterized by sudden painless
loss of central vision. In the acute stages, the optic nerve
head is swollen but later becomes atrophic [2]. Generally,
visual loss is sequential with involvement of the second eye
occurring weeks to months after the ﬁrst [3, 4]. The mode
of inheritance of LHON was thought to be X-linked, until
the ﬁrst report by Erickson in 1972, that described a non-
Mendelian pattern of inheritance involving mitochondria
[5]. In 1988, Wallace and his group reported the ﬁrst
mitochondrial DNA point mutation associated with LHON.
It was the G to A transition at nucleotide 11778 in the
ND4 gene (NADH-ubiquinone oxidoreductase, subunit 4)
of Complex I of the ETC that resulted in a substitution of
histidine for arginine at amino acid position 340.
The disease shows variable penetrance with a male
preponderance of 86% [6], and LHON is transmitted solely
through females. The expression of LHON is heterogeneous.
In some pedigrees, cardiac and neurological abnormalities
have been documented along with the characteristic optic
atrophy [7–13], loss of the retinal nerve ﬁber layer, and
ganglion cells [14]. Fibers of the papillomacular bundle are
highly sensitive to the degenerative process [15].
2. Epidemiology
There are few epidemiological studies of LHON. One of the
largest was a population-based study done in the North-
East of England. It reported a minimum point prevalence
of visual failure to be 1 in 31,000. The minimum point
prevalence was 1 in 8500 carriers of mitochondrial DNA
m u t a t i o n st ob ea tr i s ko fv i s u a lf a i l u r e[ 16]. A similar
prevalence was reported by two recent studies, one in the
Netherlands of 1 in 39,000 and the other in Finland of 12 Journal of Ophthalmology
in 50,000, respectively, [17]. Analysis of Australian pedigrees
showed approximately 0.42–2% of LHON-induced visual
loss with a variability of prevalence among men (range: 7–
58%) and women (range: 0–15%) [18]. Another study on
a Finnish population reported the incidence based on the
type of mutation. The prevalence of families with the 11778
mutation was 39% among men and 14% in women. In
families harboring the 3460 mutation, the disease expressed
in 32% of men and 15% of women [17].
3. ClinicalManifestations of LHON
PatientswithLHONtypicallypresentwithacuteorsubacute,
sudden, painless, central vision loss leading to central sco-
toma and dyschromatopsia [14]. Ophthalmoscopic exami-
nation reveals peripapillary telangiectasia, microangiopathy,
swelling of the optic nerve head, and vascular tortuosity
(Figure 1)[ 3]. This later progresses to optic atrophy. Visual
dysfunction usuallystarts at 18 to 30 yearsof age.However, it
may range from 3 to 80 years, with a mean age of onset being
2 5t o2 6y e a r si nm e na n d2 7t o2 9y e a r si nw o m e n[ 19]. In
most cases, visual deterioration is rapid and extreme, with
Snellen visual acuities of 20/200 or even worse in each eye. In
a few cases, visual loss is slow and insidious over a period of
2 years, with a mean progression time of 3.7 months.
The probability of spontaneous recovery among LHON
patients varies depending on the causative mutation. The
highest recovery rate occurs in patients with the 14484/ND6
mutation (37% in a period of 16 months). Patients possess-
ing the 11778/ND1 mutation have the poorest recovery rate
(4%) [6, 20, 21].
LHON can also be associated with minor neurological
abnormalities deﬁned as Leber’s “plus.” A study by Nikoske-
lainen et al. reported that 59% of their LHON patients
harboring any of the three primary mtDNA mutations
had neurological abnormalities [10]. Clinical manifestations
included postural tremor, motor disorder, Parkinsonism
with dystonia, peripheral neuropathy, multiple sclerosis-like
syndrome,cerebellarataxia,anarthria,dystonia,spasticity,or
mild encephalopathy [10, 22–25].
Previous reports on the inﬂuence of environmental
factors such as cigarette smoking and alcohol consumption
on LHON pathology had somewhat contrasting results [26,
27]. A recent large study by Kirkman and his group showed
no statistically signiﬁcant association of smoking to LHON.
They reported that carriers with heavy smoking habits were
greatly susceptible to developing the disease, but the eﬀects
of alcohol were not statistically signiﬁcant [28]. A single
casereportdemonstratedtheinﬂuenceofmalnutritionalong
with tobacco abuse as risk factors for LHON [29].
4.Genetics
Three-point mutations in the mtDNA respiratory chain
Complex I subunit genes: m.3460G>A/ND1 [30, 31],
m.11778G>A/ND4 [6], and m.14484 T>C/ND6 [32]a r e
associated with LHON worldwide. They constitute approx-
imately 95% of the LHON pedigrees belonging to patients of
northern European descent [33]. These three mtDNA muta-
tionsareconsideredtobetheprimarypathogenicmutations,
as they alter evolutionarily conserved amino acids, and they
are absent in the control individuals [30–32, 34]. In a small
number of LHON cases, secondary mtDNA mutations that
do not change evolutionarily conserved amino acids may
be causative. In addition, a synergistic mechanism has been
proposed whereby the secondary mutations along with the
primarymutationsincreasetheseverityofLHON[35].Since
secondary mutations are also detected in unaﬀected control
individuals,theymaysimplyrepresentpolymorphismsofthe
mitochondrial genome. The human mitochondrial genome
database (MITOMAP:www.mitomap.org) lists most of the
variants of mtDNA. A comprehensive list of all the mtDNA
mutations associated with LHON is shown in Table 1.
Since all individuals with the pathogenic mtDNA muta-
tions do not develop visual loss, the incomplete penetrance
of LHON may be due to other genetic (nuclear or mito-
chondrial) or epigenetic factors. The mtDNA haplogroup
is another major genetic determinant for LHON [36]. The
mtDNA haplogroups include the nonsynonymous variants
in Complex I and III subunit genes. European haplogroup
J is preferably associated with the 11778/ND4 (32%) and
14484/ND6(70–75%)pathogenicmutations.Thishaplotype
increases the risk of visual loss [37–39]. The haplogroup
J is further classiﬁed based on the amino acid changes in
the cytochrome b gene [40]. There is an association of
haplogroup J1 with the 14484 mutation and J1c and J2b
with the 11778 mutation, thereby indicating the inﬂuence of
speciﬁc combinations of amino acid changes inﬂuencing the
mitochondrial respiratory chain Complexes I and III [40]. In
addition, the 14484 LHON mutation showed low penetrance
whenpresentinthehaplogroupHmtDNAbackground[41].
However, the distribution of the 3460 mutation was random
among the haplotypes [37–39]. In vitro studies on cybrids
with mitochondria that carry the 11778 on the haplogroup
J background put onto the neutral nuclear background
of osteosarcoma cells had lower oxygen consumption and
delayed mitosis as compared to a nonhaplo J genotype [42].
However, another study reported no detectable diﬀerences in
respiratory function between cybrids belonging to European
h a p l o g r o u p sX ,H ,T ,o rJ[ 43]. Recently investigation of the
eﬀect of mtDNA haplogroups on the assembly of oxidative
phosphorylation (OXPHOS) complexes showed a diﬀeren-
tially delayed assembly rate of respiratory chain Complexes
I, III, and IV amongst mutants belonging to diﬀerent
mtDNA haplogroups. This indicates that speciﬁc mtDNA
polymorphisms may modify the pathogenic potential of
LHON mutations by aﬀecting the overall assembly kinetics
of OXPHOS complexes [44]. The inﬂuence of exposure to
n-hexane neurotoxic metabolite 2,5-hexanedione (2,5-HD)
on cell viability and mitochondrial function of diﬀerent cell
models (cybrids and ﬁbroblasts) carrying the LHON muta-
tions on diﬀerent mtDNA haplogroups was studied. Cell
death induced by 2,5-HD was greatly increased in LHON
cells carrying the 11778/ND4 or the 14484/ND6 mutation
on the haplogroup J background. On the other hand, the
11778/ND4 mutation in association with haplogroups U
and H signiﬁcantly improved cell survival [45]. Hence,Journal of Ophthalmology 3
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Figure 1: Fundus photographs of a patient with acute LHON revealed swelling of the right (a) and left (b) optic nerve heads. The arrow
indicates the characteristic peripapillary telangiectasia. Automated visual ﬁelds showed central scotomas in the left (c) and right (d) eyes.
OCT conﬁrmed and quantitated the swelling of the retinal nerve ﬁber layer (e). Pattern electroretinograms illustrated a decline in ganglion
cell function occurred during the acute stages of LHON and before structural evidence of RGC loss (f).4 Journal of Ophthalmology
Table 1: Comprehensive list of genes/mutations involved in LHON.
Genes Gen Bank ID Nucleotide
position AA change Phenotype Hom/Het Reference
MT-ND1 ACT53094.1
m.3316G>A A4T LHON/NIDDM Hom Matsumoto et al., 1999 [122]
m.3376G>A E24K LHON/MELAS Hom/Het Blakely et al., 2005 [123]
m.3394T>C Y30H LHON/NIDDM Hom Brown et al., 1992 [124]
m.3460G>A A52T LHON Hom/Het Huoponen et al., 1991 [30]
m.3496G>T A64S LHON Hom Matsumoto et al., 1999 [122]
m.3497C>T A64V LHON Hom Matsumoto et al., 1999 [122]
m.3635G>A S110N LHON Hom Brown et al., 2001 [125]
m.3700G>A A112T LHON Hom Fauser et al., 2002 [126]
m.3733G>A E143K LHON Hom/Het Valentino et al., 2004 [127]
m.4025C>T T240M LHON Hom Huoponen et al., 1993 [128]
m.4136A>G Y277C LHON Hom Howell et al., 1991 [129]
m.4160T>C L286P LHON Hom Howell et al., 1991 [129]
m.4171C>A L289M LHON Hom/Het Kim et al., 2002 [130]
m.4216T>C Y304H LHON/Insulin resistance Hom Johns and Berman, 1991 [131]
MT-CO1 ACT53096.1
m.6261G>A A120T LHON/Prostrate Cancer Hom Abu-Amero and Bosley et al.,
2006 [132]
m.7444 G>A Ter-K LHON/SNH/DEAF Hom Brown et al., 1992 [133]
m.7623 C>T T13I LHON Hom Abu-Amero and Bosley et al.,
2006 [132]
MT-CO2 ACT53097.1 m.7868C>T L95F LHON Hom Yang et al., 2009 [134]
MT-ND2 ACT53095.1
m.4640C>A I57M LHON Hom Brown et al., 2001 [125]
m.4917A>G N150D LHON/AMD/Insulin
resistance/NRTI-PN Hom Johns and Berman, 1991 [131]
m.5244G>A G259S LHON Het Brown et al., 1992 [135]
MT-ND3 ACT53101.1 m.10237T>C I60T LHON Hom Horvath et al., 2002 [136]
MT-ND4 ACT53103.1
m.11253T>C I165T LHON Hom Kjer 1959 [137]
m.11696G>A V312I LHON+Spastic Dystonia Het De Vries et al., 1996 [138]
m.11778G>A R340H LHON Hom/Het Wallace et al., 1988 [6]
m.11874C>A T372N LHON Hom Abu-Amero and Bosley et al.,
2006 [132]
MT-ND4L ACT53102.1
m.10543A>G H25R LHON Het Abu-Amero and Bosley et al.,
2006 [132]
m.10591T>G F41C LHON Het Abu-Amero and Bosley et al.,
2006 [132]
m.10663T>C V65A LHON Hom Brown et al., 2002 [139]
m.10680G>A A71T LHON Hom Yang et al., 2009 [134]
MT-ND5 ACT53104.1
m.12782T>G I149S LHON Het Abu-Amero and Bosley et al.,
2006 [132]
m.12811T>C Y159H LHON Hom Huoponen et al., 1993 [128]
m.12848C>T A171V LHON Het Mayorov et al., 2005 [140]
m.13045A>C M237L LHON/MELAS/LS Het Liolitsa et al., 2003 [141]
m.13051G>A G239S LHON Hom Howell et al., 2003 [142]
m.13379A>C H348P LHON Hom Abu-Amero and Bosley et al.,
2006 [132]
m.13528A>G T398A LHON-Like Hom Batandier et al., 2000 [143]
m.13637A>G Q434R LHON Hom Huoponen et al., 1993 [128]
m.13708G>A A458T LHON/MS risk Hom Johns and Berman, 1991 [131]
m.13730G>A G465E LHON Het Howell et al., 1993 [144]Journal of Ophthalmology 5
Table 1: Continued.
Genes Gen Bank ID Nucleotide
position AA change Phenotype Hom/Het Reference
MT-ND6 ACT53105.1
m.14568C>T G36S LHON Hom Besch et al., 1999 [145]
m.14279G>A S132L LHON Hom Zhadanov et al., 2005 [146]
m.14459G>A A72V LHON+Spastic Dystonia Hom/Het Jun et al., 1994 [147]
m.14482C>G M64I LHON Hom/Het Howell et al., 1998 [148]
m.14484T>C M64V LHON Hom/Het Brown, et al., 1992 [124]
m.14495A>G L60S LHON Het Chinnery et al., 2001 [149]
m.14498C>T Y59C LHON Hom/Het Wissinger et al., 1997 [150]
m.14596A>T I26M LHON Hom De Vries et al., 1996 [138]
m.14325T>C N117D LHON Hom Howell et al., 2003 [142]
m.14729G>A S132L LHON Hom Zhadanov et al., 2005 [146]
MT-CYB ACT53106.1
m.14831G>A A29T LHON Hom Fauser et al., 2002 [126]
m.14841A>G N32S LHON Het Yang et al., 2009 [134]
m.15257G>A D171N LHON Hom Johns and Berman, 1991 [131]
m.15674T>C S310P LHON Hom Abu-Amero Bosley et al., 2006
[132]
m.15773G>A V343M LHON Hom La Morgia et al., 2008 [151]
m.15812G>A V356M LHON Hom John et al., 1991 [152]
MT-CO3 ACT53100.1
m.9438G>A G78S LHON Hom Johns and Neufeld 1993 [153]
m.9738G>T A178S LHON Hom Johns and Neufeld 1993 [153]
m.9804G>A A200T LHON Het Johns and Neufeld 1993 [153]
MT-ATP6 ACT53099.1
m.8836A>G M104V LHON Hom Abu-Amero Bosley et al., 2006
[132]
m.9016A>G I164V LHON Het Povalko et al., 2005 [154]
m.9101 T>C I192T LHON Hom Puomila et al., 2007[17]
m.9139G>A A205T LHON Hom La Morgia et al., 2008 [151]
the mtDNA haplotypes might act in association with the
pathogenic mtDNA mutations to somehow modulate the
phenotypic expression of LHON.
5.Heteroplasmy andIncomplete Penetrance
LHON exhibits incomplete penetrance with a male pre-
dominance. Approximately half of the men and 10% of
females harboring one of the three pathogenic mtDNA
mutations develop visual loss. This suggests that additional
genetic factors and/or environmental factors modulate the
phenotypic expression of LHON. The male preponderance
in the disease manifestation could be also due to other
anatomical, hormonal, or physiological factors [46].
Generally, cells contain 100–10,000 mitochondria, and
each organelle harbors 2–10 mtDNA molecules. The copy
number of mtDNA is therefore very high and shows
heterogeneous distribution in diﬀerent tissues based on the
energy requirements [47]. Homoplasmy is deﬁned as all
the mitochondria of the cell possessing either wild-type or
mutant mtDNA. When there is a mixture of wild-type and
mutant mtDNA, it is called heteroplasmy. In the majority
of LHON patients and family members, the pathogenic
mtDNA mutation is homoplasmic. Still, 14% of the LHON
members have the mutation in heteroplasmic condition
[48]. Clinically, there are no diﬀerences among the aﬀected
homoplasmic individuals from heteroplasmic patients [35].
Jacobi et al. reported variable prevalence of heteroplasmy
based on the type of mutation possessed in 167 genealogi-
callyunrelatedLHONfamilies.Individualswith11778/ND4,
3460/ND1, and 14484/ND6 mutations showed levels of het-
eroplasmy equal to 5.6%, 40% and 36.4%, respectively, [49].
However, a study analysing four large Thai LHON pedigrees
showed a prevalence of 37% of heteroplasmic 11778/ND4
mtDNA [50, 51]. In heteroplasmic families, the level of
heteroplasmy can vary extensively between generations and
also between oﬀspring in the same family due to a genetic
bottle neck eﬀect of mitochondrial distribution occurring in
the early stages of oocyte formation [48, 52–55].
In addition, there have been controversial reports on the
distribution of mutant mtDNA in diﬀerent tissues. Yen et
al. compared the mutant mtDNA from the leukocytes and
hair follicles in an LHON proband carrying the 11778/ND4
mutation and observed mtDNA heteroplasmy in the hair
follicle cells, but not in blood cells. This ﬁnding indicated the
tissue variability in distribution of the wild-type to mutant
mtDNA [56]. However, another report demonstrated com-
parable levels of mtDNA heteroplasmy in the blood, hair,6 Journal of Ophthalmology
and urinary tract epithelia of LHON patients carrying the
11778/ND4 mutation [57].
In someheteroplasmic LHONfamilies, anincreasein the
proportion of the mutant mtDNA in successive generations
has been observed [48, 54]. This ﬁnding suggests a positive
selection pressure. However, Puomila et al. quantiﬁed the
level of heteroplasmy of the mtDNA mutations 11778/ND4
and 3460/ND1 in blood samples over a period of 4–12 years
from nine members of four heteroplasmic LHON families.
No major shift in heteroplasmy was demonstrated, thus no
selection of either mtDNA genotypes. They proposed that
the segregation of the wild-type mtDNAs and those carrying
LHONmutationsisastochasticprocessgovernedbyrandom
genetic drift. In this respect, LHON mutations seem to
behave like neutral polymorphisms [58]. These observations
indicate that the role of selection is questionable.
The risk of visual failure in LHON increases as the
threshold of heteroplasmy of primary pathogenic mtDNA
mutations is increased to approximately 75%–80% [59].
The eﬀect of heteroplasmy on phenotypic expression does
not appear to be related to gender [60]. Howell et al.
demonstrated in autopsied specimens of a woman with
the 11778/ND4 mutation that the mutant mtDNA level
was higher in the optic nerves (95%) and retina (100%)
compared to circulating blood leukocytes (33%) [54]. This
ﬁnding suggests that the susceptibility of certain tissues is
duetotheirhigherthresholdofmutanttowild-typemtDNA.
However, in a family of LHON, one of the two brothers with
98% mutant mtDNA lost vision, while his brother who had
100% mutant mtDNA was asymptomatic. Still, their ocular
levels of mutated mtDNA were not evaluated.
Theproposedriskfordiseaseexpressioninhomoplasmic
families is only 30–50% in males and 5%–15% in females
[35]. Chinnery et al. studied 17 independent LHON pedi-
grees to determine the risk of transmission of LHON in
heteroplasmic families. He reported that mothers with 80%
orlessmutantmtDNA(measuredinbloodleuckocytes)were
less likely to have clinically aﬀected sons than mothers with
100% mutant mtDNA [61].
6.Mechanismsof CellDeathinLHON
Despite the presence of the mtDNA mutation in all retinal
cells, it is predominantly RGCs of the papillomacular bundle
region of the retina and their axons in the optic nerve that
undergo degeneration in LHON. Why the disease spares
other cell types such as the photoreceptors and the retinal
pigment epithelium is unclear but may in part be due to
the unique energy demands of RGCs, with their long axons
and transition from unmyelinated to myelinated ﬁbers in the
retrobulbar nerve. Mitochondrial dysfunction from energy
depletion has been proposed to disrupt axonal transport
[61, 62]. Axonal transport is driven by the motor proteins
kinesin and dyenin, both of which require large amounts of
ATPforthisfunction[61].Therefore,proteinssynthesizedin
the RGC cytoplasm as well as the mitochondria themselves
that do not move down the axon towards the brain may
contribute to the visual loss and degeneration of LHON.
As most LHON mutations involve the NADH-
ubiquinone oxidoreductase, a decrease in Complex I
activity resulting in apoptotic cell death is paramount
[63]. LHON cybrids grown in galactose media, as the
sole carbon source, force the cells to rely on oxidative
phosphorylation rather than glycolysis to generate ATP.
Under such restrictive conditions, LHON cells with mutated
mitochondrial DNA undergo apoptotic cell death in a
calcium [Ca(2+)-]dependent [64] and caspase-independent
pathway [65, 66]. In addition, cytochrome c along with the
apoptosis inducing factor (AIF) and endonuclease G (Endo
G) are released from the mitochondria into the cytosol.
Control cells with normal mitochondrial DNA remained
unaﬀected by this restrictive media [65]. Cells harboring
the 3460 and 14484 mtDNA mutations in the same nuclear
background were comparitively more sensitive to apoptotic
death than those harboring the 11778 mtDNA mutation.
Battisti et al. treated the peripheral blood lymphocytes of
LHON patients and controls with 2-deoxy-D-ribose and
found a higher apoptotic rate in cells of LHON patients
in comparison to controls, thus indicating mitochondrial
involvement in this susceptibility [67].
In addition, mechanisms relating to increased oxida-
tive stress have been proposed in LHON pathophysiology.
Studies on the osteosarcoma-derived cybrids made from the
mitochondria of LHON patients, carrying the 11778/ND4,
3460/ND1, or the 14484/ND6 mtDNA mutations, showed
an excitotoxic mechanism of impaired glutamate transport.
Defective activity of the excitatory amino acid transporter 1
(EAAT1) led to oxidative stress and increased mitochondrial
ROS within RGCs. This in turn contributed to the apoptotic
pathway of cell death of RGCs, loss of axons, and optic nerve
atrophy [68].
In a study of oxidative stress of a cell line previously
thought to be of RGC lineage (RGC-5), it was found that
endogenous levels of superoxide anion were signiﬁcantly
lowerthanthatfoundinneuronsoftheratbrain.Increasesin
ROS caused by mtDNA mutations that trigger the apoptotic
cascade in ganglion cells of the retina may be better tolerated
by neurons of the brain [69]. That mitochondrial DNA
mutations result in Fas-induced apoptosis were demon-
strated in osteosarcoma-derived cybrid cells carrying the
11778/ND4 or 3460/ND1 mutations. Control cells with the
same mitochondrial halogroup J, but without the pathogenic
G11778A mutation, were not sensitive compared to other
controls. This ﬁnding indicates the pathogenicity of the
LHON mutations [70]. Figure 2 shows potential pathways
implicated in the optic nerve degeneration of LHON, as
deduced from cellular and animal models.
7. CurrentTherapies
ManagementofLHONhasbeensupportive,primarilybythe
use of low-vision aids. Current therapies are inadequate, but
they deserve mention. The mainstay of treatment includes
pharmaceutical compounds that are believed to restore
electron ﬂow or increase antioxidant defenses. One of these
agents is idebenone, a short chain derivative of coenzymeJournal of Ophthalmology 7
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that culminate in the optic nerve degeneration of LHON and LHON cellular and animal models. ATP—adenosine triphosphate; ROS—
reactive oxygen species.
Q10 (CoQ10)[ 71–73]. Mashima et al. used idebenone
combined with vitamin B2 and vitamin C, to “stimulate
ATP formation” in LHON patients. Treatment for at least
one year hastened the recovery process. Visual improvement
that was deﬁned as being greater or equal to 0.3 logMAR
occurred within 17.6 months of treatment relative to 34.4
months without it [73]. In another report of idebenone
and vitamin B12 therapy, a North African LHON patient
harboring a homoplasmic 14484/ND4 mtDNA mutation
recovered vision. Serum lactate levels normalized over a
period of 3.5 months [72]. In contrast, two other patients
who were treated with idebenone and multivitamins failed
to improve [74]. The eﬀectiveness of idebenone therapy for
LHONiscurrentlythesubjectofacontrolleddouble-masked
randomized study in Europe and Canada. While the results
of a recent press release were favorable, details have not yet
been published.
The clinical phase of the patient at which time therapy
is initiated might determine treatment outcome. As a
prophylactic measure to prevent vision loss, a topically
applied agent, brimonidine purite 0.15% (Alphagan), with
potentially antiapoptotic properties was administered to the
as yet unaﬀected eyes of LHON patients. Unfortunately,
this therapy proved unsuccessful in preventing them from
undergoing visual loss. Thus, the study was terminated after
enrollment of only 8 patients [75]. The search for an eﬀective
treatment continues.
8. AnimalModels
The genetics of LHON have steadily accumulated for more
than two decades. However, the pathogenic mechanisms
leading to the apoplectic visual failure with subsequent
retinal ganglion cell and optic nerve degeneration that could
lead to the development of an eﬀective treatment strategy are
poorly understood. This is in large part due to the lack of
bonaﬁdeanimalmodelsforLHON.Thedeﬁciencyofanimal
models is also a general problem for most mitochondrial
diseases, where the complete deletion of any subunit of
the respiratory chain often results in a lethal phenotype
[76]. Still, using diﬀerent approaches, a few animal models
resembling LHON have been generated in recent years. The
ﬁrst animal model for LHON was made by Zhang and his
group by administering rotenone, an irreversible Complex
I inhibitor, to mice. Histologic analysis showed thinning of
the RGC layer, by 43%, one day after the rotenone injections
[77].
Next, Qi et al. used a genetic approach to knockdown
Complex I activity. They designed ribozymes to degrade
the mRNA encoding a critical nuclear-encoded subunit gene
of Complex I (NDUFA1). It markedly reduced Complex I
activity in murine cells. Using the AAV vector as a vehicle
to deliver the ribozymes into the mouse vitreous cavity,
the authors found loss of RGCs and axons that resembled
the histopathology of LHON [78]. This model system
also implicated oxidative stress in the pathogenesis of the
degenerative process.
As further evidence for involvement of ROS in optic
nervedegeneration,intraocularinjectionsofAAV-expressing
hammerhead ribozymes designed to degrade mitochondrial
superoxide dismutase (SOD2) mRNA induced further loss
of axons and myelin in the optic nerve and ganglion cells
of the retina, the very hallmarks of LHON histopathology
[79]. RGC and axonal loss were ameliorated by intraocular8 Journal of Ophthalmology
injections of an AAV overexpressing SOD2 into eyes that
also had received the NDUFA1 ribozymes [80]. Later, Qi
and associates proposed augmenting mitochondrial antiox-
idative defensive mechanisms to rescue cybrid cells with
the G11778A mutation in mtDNA from galactose-induced
apoptotic cell death by infecting them with AAV-SOD2.T h e
control cells were treated with AAV-GFP (green ﬂuorescent
protein). Within 2 and 3 days of growth in galactose media,
LHON cell survival increased by 25% and 89%, respectively,
[81]. The ROS superoxide anion has recently been shown
to mediate apoptosis in RGCs [82]. Dismutation of the
superoxide anion by SOD suppressed RGC apoptosis. Taken
together, these ﬁndings suggest that antioxidant genes may
oﬀer a therapeutic strategy directed at the pathophysiologic
mechanisms of LHON.
Still, it was unclear whether such ﬁndings in those mouse
models are truly representative of events in LHON patients.
The ribozyme and rotenone animal models illustrate the
pathogenic eﬀects of severe loss of Complex I activity in
the vertebrae visual system. However, the activity of the
NADH-ubiquinone oxidoreductase is reduced only slightly
in cells with the G11778A mtDNA. To generate a more
representative animal model of LHON, Qi and associates
constructed a mutant ND4 subunit gene that was designed
to express the arginine-to-histidine substitution at amino
acid 340 characteristic of the mutant human LHON ND4
protein [83]. Delivery of this construct with the AAV vector
injectedintothemousevitreouscavityresultedinopticnerve
head swelling. Several months later, the optic nerve became
atrophic and ganglion cells of the retina were lost. Both
optic nerve head swelling and visual loss are characteristics
of acute LHON. They are followed by optic atrophy. Thus,
the phenotype of the murine model and the human disease
appear comparable.
Ultrastructural analysis of mutant ND4-injected eyes
revealed disruption of mitochondrial cytoarchitecture, ele-
vated reactive oxygen species that culminated in apoptosis
of RGCs [83]. Mouse eyes injected with AAV containing
the normal human ND4 showed no evidence of pathology
whatsoever. Since the mutant and human ND4 constructs
diﬀered only in the arginine to histidine transition at
amino acid 340 (mutant ND4), these studies aﬃrm that
the pathogenicity of this mutation is the cause of LHON.
Ellouze et al. who later introduced the mutant human ND4
gene into rat eyes found that it caused RGC degeneration
and a decline in visual performance [84]. An important
diﬀerence between human LHON and rodent models is
worth mentioning. Disease in rodents occurred even in the
presence of endogenous mouse (or rat) ND4. In human
LHON, wild-type ND4 is typically absent. That being the
case, rescue of the LHON rodent model by the addition of
more wild-type ND4 may not be possible.
9. GeneticTherapy and FutureDirections
Curative treatments for mitochondrial disorders are cur-
rently lacking. However, extensive exciting research advances
are being made. One of the most promising emerging
technologies is “allotopic expression,” wherein a nuclear
version of the mitochondrial gene is constructed by partially
recoding the mtDNA gene in the nuclear genetic code. It
was through allotopic expression of the mutant human ND4
subunit gene that an LHON-like phenotype was induced in
rodentmodelsasdiscussedintheprevioussection.Changing
the ATA codon to ATG is necessary to achieve allotopic
expression, since the ATA encodes for methionine in mito-
chondria, but isoleucine in the nucleus. In addition, the TGA
codon that speciﬁes tryptophan in mitochondria is a stop
codon in the nucleus. Therefore, this codon must also be
corrected for the full-length ND4 protein to be translated on
cytoplasmic ribosomes. Protein import into mitochondria is
then directed by the addition of a mitochondrial targeting
sequence (MTS) to the amino terminus [85, 86]. Protein
expression can then be monitored with an epitope tag
appended to the carboxy terminus. Guy et al. were the ﬁrst
to use this approach with a human ND4 gene to rescue
the defects of oxidative phosphorylation in G11778A LHON
cells [86]. They constructed a synthetic ND4 subunit from
overlapping 80mer oligonucleotides. After packaging in an
adenoassociated viral vector, it was used to transduce cells
harboring 100% G11778A-mutated mtDNA. One of their
constructs successfully increased ATP synthesis by threefold
in LHON cell lines relative to controls treated with GFP or
transducedwiththesameND4genethathadadiﬀerentMTS
and epitope tag that was not imported into the mitochondria
[86].
Last year, our group demonstrated that allotopic delivery
of the normal human ND4 subunit gene into the vitreous
cavity of the murine eye is safe. There was no diﬀerence
in total RGC counts, measured as Thy1.2 positive cells,
between these experimental eyes and controls injected with
AAV-GFP. Moreover, the pattern and ﬂash electroretinogram
amplitudes after the injections remained unchanged from
their baseline values before the injections. This important
ﬁnding indicates that injection of the allotopic human ND4
did not compromise murine RGC function [87]. Using
immunoprecipitation of the 45 subunit Complex I, we
demonstrated that the FLAG-tagged human ND4 incorpo-
rated into the holoenzyme of infected murine retinal and
optic nerve tissues. To validate the technique, we submitted
nine bands pulled down by Complex I immunoprecipitation
of murine mitochondria isolated from the optic nerve, brain,
spinal cord, or retina for identiﬁcation by mass spectroscopy.
They were positively identiﬁed as subunits of the NADH-
ubiquinone oxidoreductase (Figure 3). No other respiratory
Complexes (II–V) were detected. Therefore, the FLAG-
tagged human ND4 detected by this assay proves that it
eﬀectively integrated into the murine Complex I.
Prior evidence of cross complementation in dissimilar
mammalian species was previously shown by Tsukihara
and coworkers [88], where a bovine allotopic COX1 had
integratedintothehumancytochromeoxidaseenzyme.They
used blue-native electrophoresis to pull down the assembled
COX holoenzyme. Using this technique, Figueroa-Mart´ ınez
and coworkers [89] were unable to ﬁnd integration of their
construct that used a short COX6 MTS to direct import of
ND6 tagged with hemagglutinin (HA), the only constructJournal of Ophthalmology 9
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Figure 3: Electrophoresis of mitochondrial proteins isolated from
the mouse brain following Complex I immunoprecipitation and
counterstained by Coomassie blue are shown in the second lane.
The ﬁrst lane has the molecular weight standards. The table
indicates the identity of bands submitted for mass spectroscopy to
be subunits of Complex I. (∗)—subunits identiﬁed within the same
excised band. (nd)—not determined.
tested. Brookes and coworkers [90] used mass spectroscopy
to identify more than 30 bands that were separated by 2D
blue-native PAGE. Of these bands, a single 33 kilodalton
(kDA) subunit of Complex I was identiﬁed [90]. In addition,
the authors pulled down many proteins that were not res-
piratory complexes. The authors further go on to show that
inhibitionofmitochondrialproteinsynthesisofhydrophobic
mtDNA-encoded proteins with chloramphenicol did not
alter the assembly of respiratory complexes, as judged by
blue-native electrophoresis. Therefore, unambiguous data
showing that hydrophobic Complex I subunits are isolated
by blue-native electrophoresis has yet to be demonstrated.
Using electron microscopy as further evidence of allo-
topic import, ND4 labeled by immunogold decorated the
interior of the organelle and it colocalized with MnSOD
[83, 87]. The latter is a nuclear-encoded mitochondrial
protein that too is imported into the organelle along with
85% of all mitochondrial proteins that are encoded by the
nucleus. Had the ND4FLAG immunogold been stuck in the
membrane pores as suggested by Oca-Cossio [91]i tw o u l d
have decorated the exterior of the organelle as shown by
Gilkerson and colleagues [92] for the membrane protein
porin. Thus, the allotopic ND4 protein did not get stuck in
the mitochondrial import channels or induce cell death as
suggested by Oca-Cossio and coworkers [87, 91]. Injections
of wild-type human ND4 also had a small, but quantiﬁable,
biological eﬀect that was manifested by shortening of the
pattern electroretinogram (PERG) latency. The implications
of this ﬁnding are unclear. With the mouse and human ND4
being approximately 80% homologous and amino acid 340
being highly conserved, along with the fact that the latency
of the mouse PERG is almost double that of humans, it is
tempting to speculate that human ND4 integration into the
mouse Complex I made the mouse RGC responses faster
than that observed in control eyes. This may reﬂect an
evolutionary adaptation of the human respiratory chain for
the relatively fast RGC responses required in man.
Controversies in allotopic expression based entirely on
studies of cultured cells continue to be debated in the recent
literature. However, they have shifted somewhat from the
views of Oca-Cossio [91] that showed no colocalization of
allotopic proteins (except ATP8) with a bona ﬁde mitochon-
drial marker to those now showing colocalization suggestive
of import, but lacking integration into functional respiratory
complexes [89]. In 2002, Guy et al. showed that LHON
cells expressing the same allotopic human ND4, but fused
to a diﬀerent mitochondrial targeting sequence (aldehyde
dehydrogenase) or epitope tag (GFP) did import into the
mitochondria [86]. Consistent with this ﬁnding, the latter
construct did not rescue LHON cells from glucose-free
galactose media-induced cell death or improve their ATP
synthesis.
In support of a paramount role for the MTS in directing
mitochondrial traﬃcking, Superkova and coworkers [93]
showed that the allotopic import of a mutant COX2 was
dependent on the mitochondrial targeting sequence, but
not the mitochondrial targeting 3 UTR. Still, the studies
of Bonnet et al. [94] clearly demonstrated the beneﬁts of
the COX10 3 UTR when used in conjunction with the CIS
acting elements of the COX10 MTS. Relative to controls,
the COX10-ND4 or COX10-ND4 3 UTR constructs each
increased G11778A LHON cell survival in galactose media
and improved their ATP synthesis. Their ﬁndings support
the earlier studies of Guy and coworkers’ successful allotopic
ND4 import into mitochondria. Clearly, the testing of
constructs for allotopic expression that include the mito-
chondrial targeting sequence, protein, epitope tag, or 3 UTR
is largely a trial-and-error endeavor [95]. Since cell culture
studies can sometimes be misleading [96], conﬁrmation in
appropriate animal models is vital to demonstrating the
safety and eﬀectiveness of allotopic ND4 expression before
it can be applied to LHON patients.
Using their MTS and 3 UTR model system, Ellouze and
colleagues introduced the mutant human ND4 subunit gene
harboring the G11778A mutation into rat eyes, by in vivo
electroporation. This led to loss of vision and degeneration
of almost half the RGCs, as previously described by Qi
and coworkers [83]. By introducing a normal copy of the
human ND4 gene, visual and RGC loss were averted [84].
Thus, the data accumulated to date provide overwhelming
evidence that allotopic expression of a mutant ND4 causes
RGC degeneration and a wild-type version does not. More
importantly, theyshow thatthewild-typeND4 canrescuean
LHON animal model. Clearly, allotopic delivery of a normal
ND4 is a promising approach in the quest for an eﬀective
remedy for LHON caused by mutated G11778A mtDNA.
For this to occur, an eﬀective and safe delivery system
is necessary for ND4 gene therapy. The single-stranded (ss)
AAV2 used in allotopic mouse experiments has been proven
safe in several phase I human ocular gene therapy trials [97].
Thus, the AAV vector has a proven track record in human
clinical trials [98–101]. There has been extensive research on
these viral vectors with much advancement, particularly in10 Journal of Ophthalmology
the areas of transduction eﬃciency, stability, tropism, and
most importantly safety. The retinal layer exclusively aﬀected
in LHON can be targeted by optimizing the vector serotype
(AAV2), and by choosing the route of vector administration
(intravitreal injection).
Newer generation vectors include the self-comple-
mentary (sc) AAV that contains both positive and negative
complementary strands. Since second strand synthesis is
believed to be the rate-limiting step for expression of single-
stranded vectors, it is not surprising that scAAV vectors
increase the speed and eﬃciency of transgene expression
[102–104]. Other AAVs with mutations in the capsid pro-
teinsalsoincreasetheeﬃciencyoftransgeneexpression[105,
106]. They were designed to reduce cellular degradation
of AAV, thus increasing cellular levels of AAV virions. By
taking advantage of scAAV to deliver the allotopic ND4 into
the mouse eye, our group doubled RGC expression relative
to the single-stranded AAV that is the current standard
vehicle for gene delivery. With scAAV, FLAG-tagged ND4
was seen in almost all murine RGCs (90%) [107]. Such
newer generation vectors may be highly advantageous for
LHON gene therapy. They can be used at lower doses, thus
minimizing immunologic responses against the viral capsid
that could prevent expression of ND4 and also with maximal
eﬃciency [108]. This could have important implications
for treatment of LHON patients, where prior injection into
the ﬁrst eye, should it generate an immune response, may
limit expression with later injections of AAV-ND4 into the
second eye. LHON is a bilateral disease, thus both eyes need
treatment.
Great care must be taken in extrapolating the results
achieved in rodents to the human disorder, particularly
under pathological conditions. As an example, immuno-
precipitation of Complex I following intravitreal injections
of the normal allotopic human ND4 revealed a greater
distribution of the FLAG-tagged ND4 in the murine optic
nerve than that observed in the retina [87]. In contrast,
the mutant ND4 had greater incorporation into the murine
retina than in the optic nerve [83]. These ﬁndings suggest
that cellular events associated with the optic disc edema
may impede movement of the ND4 integrated into the
holoenzyme from the retina to the nerve. The studies of
Oca-Cossio suggest that if ND4 is not correctly processed
into mitochondria, it may be harmful [91]. In addition, if
LHON is primarily an axonopathy, then the allotopic ND4
may not get to the target tissue (axonal mitochondria in the
optic nerve) for rescue in acute LHON patients who typically
have optic nerve head swelling. On the other hand, if LHON
is primarily a disorder of RGCs, then it will rescue. Further
studies in lower vertebrates are needed to delineate the best
window for intervention.
Manyotherexperimentaltechniqueshavebeenproposed
to address disorders caused by mutated mtDNA. They
include mitochondrial gene replacement in embryonic stem
cells [109], protoFection [110], importing genes from other
species, changing the ratio of heteroplasmy with speciﬁc
restriction endonucleases [111], or selecting for respiratory
function or regeneration (in muscle) [112, 113]. None of
these techniques are directly applicable to the treatment
of LHON that is caused predominantly by 100% mutated
mtDNA. An approach worth mentioning here is that
of transkingdom allotopic expression coined “xenotopic
expression.” This technique was pioneered by Ojaimi and
coworkers, who experimentally restored defects in Complex
V of the electron transport chain [114]. Using a similar
approach, Seo et al. used the NDI1 gene of Saccharomyces
cerevisiae to rescue the respiratory deﬁciency of Complex
I deﬁcient Chinese hamster CCL16-B2 cell lines [115].
The NDI1 gene is a single subunit NADH-ubiquinone
oxidoreductase that appears to perform the function of the
45 subunit mammalian Complex I. NDI1 is encoded in
the nuclear genome, expressed on cytoplasmic ribosomes,
and successfully transported into the mitochondrial inner
membrane with an N-terminus mitochondrial targeting
sequence.
The Yagi laboratory has applied their NDI1 technology
to alleviating the consequences of a human cell line carrying
a homoplasmic frame shift mutation in the ND4 gene
[116]. Recently, they utilized an AAV expressing NDI1
to rescue the Complex I deﬁciency induced by rotenone
in the mouse visual system [117]. Xenotopic technology
has the advantage whereby a single construct, NDI1, can
treat all LHON cases caused by mutated ND4, ND1, or
ND6 Complex I subunits. Allotopic expression of human
Complex I subunits requires three separate constructs, one
for each of the three mutated subunit genes. Still, it is
unclear whether introduction of a gene from an entirely
diﬀerent species is acceptable for human therapy. Moreover,
it has not been demonstrated how NDI1 interacts with
Complexes II–V of the human respiratory chain. A recent
publication showing the extension of the ﬂy lifespan with
the NDI1 gene suggests that the mechanism of beneﬁt was
not achieved by improving oxidative phosphorylation, but
rather by decreased production of ROS [118]. Still, who
is an appropriate candidate for allotopic or xenotopic gene
therapy?
10. Candidatesfor GeneticTherapies
The stage of disease may dictate the outcome of gene
therapy. Lam and coworkers found that optical coherence
tomography (OCT) measurements of the retinal nerve ﬁber
layer (RNFL) averaged 72µm for as long as 3 years after
visual loss [119]. After this time, RNFL thickness dropped
to 42µm. With loss of more than half of their RGCs, these
late-stage patients may not have a suﬃcient population of
remaining cells for meaningful rescue of vision. Still, the
scAAV that expressed in almost all RGCs of the mouse has
the potential to restore function even in those remaining
axons described in autopsied LHON eyes as exhibiting
accumulation of mitochondria and dissolution of cristae
[15]. If so, visual function may improve even with long-
standingopticatrophy.Thatthismaybepossibleissuggested
by the Leber’s congenital amaurosis (LCA) clinical trials
where partial return of visual function occurred even in eyes
with severe and long-standing photoreceptor loss [97, 120,
121].Journal of Ophthalmology 11
The rapidity of gene expression is clinically relevant
in treating LHON patients who present with bilateral
simultaneous onset of acute visual loss. Still, oxidative injury
and apoptosis may already be irreversible at this time.
Considering the window period of 2–3 months between the
involvement of the ﬁrst and the second eye, treatment may
even be employed before loss of vision. Thus, rescue prior
to visual loss in the second eye may be possible during this
window period, particularly if introduction of the normal
ND4 subunit gene in those eyes with acute optic disc edema
after visual loss proves ineﬀective.
The studies of Elouze et al. suggest that gene therapy pre-
ventsvisuallossinlowervertebrates[84].Whethersuccessful
rescue in symptomatic patients will support intervention in
asymptomatic carriers may be dependent on tests capable of
predicting conversion to the phenotype. Using the PERG as a
sensitive measure of ganglion cell function, Lam et al. found
that the PERG amplitude was substantially reduced in some
asymptomatic G11778A carriers [119]. They plan to follow
those patients for several years to see if they develop LHON.
In summary, due to the research of many groups all
over the world who are working in the ﬁeld, the molecular
and biochemical basis of this disease has been unraveling.
Eﬃcient gene delivery techniques tested in vertebrae animal
models that mimic the optic nerve degeneration of LHON
provide a renewed hope for an eﬀective and long-lasting
remedy for this disorder in the coming years.
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